Molekule Group, Inc. announced the results of a research study evaluating the effect of in-room air purification on the clinical recovery in mild and moderate COVID-19 patients. The study, conducted at two Mercyhealth hospitals, indicates a statistically significant outcome, with length of stay reduced by approximately two days when Molekule's Air Pro purifier with its patented PECO filter is running in the patient room. Key Details from the Study: The placecebo-controlled trial was conducted for one year (January 2022 to December 2022) at two Mercyhealth hospital locations in Wisconsin and Illinois.

The results showed a significant difference in the length of stay with the use of the Air Pro device with a patented PECO filter compared with no filter (placebo). On average, patients with Air Pro devices with filter use stayed two days less in the hospital compared with placebo devices. Molekule has the range of proprietary and patented FDA-cleared air purification devices, which have been proven to destroy SARS-CoV-2, H1N1 flu virus, VOCs, allergens, mold and many other airborne pollutants.

Molekule's patented photo electrochemical oxidation (PECO) technology, with FDA clearance for medical use, is one-of-a-kind in its capability to not only capture, but break down pollutants like bacteria, viruses, mold, allergens & more. Molekule devices are the only air purifiers to use patented PECO technology to destroy pollutants. The devices are part of a advanced solutions platform, which includes IAQ monitoring and internet-of-things ("IoT") device control.

Molekule technology can measure the temperature, humidity, CO, VOCs, PM-1, PM-2.5, PM-10, ozone and indoor CO(2) concentrations anywhere deployed in buildings and other indoor spaces.